Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm and TCGLS Enter Into an Exclusive Research Agreement

Published: Tuesday, September 10, 2013
Last Updated: Tuesday, September 10, 2013
Bookmark and Share
Collaboration to develop a novel class of antibiotics, a new strategic therapeutic area for Debiopharm.

Debiopharm Group™ (Debiopharm) and TCG Lifesciences Limited (TCGLS) have announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections.
 
Debiopharm is willing to become a key player in the area of antibacterials to fulfill the increasing need of new classes of antibiotics to overcome resistance to current treatment.

Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimization of lead compounds whilst Debiopharm will provide drug development expertise and fund the development program.

“We foresee to increase our commitment in this field over next few months through additional partnerships and investments on other innovative targets” said David Deperthes, VP Business Development & Licensing.

"We are very enthusiastic about this partnership with TCGLS for the development of novel antibiotics, their extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348. This partnership is key to us to establish a leadership position in the area of antibiotics” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Swapan Bhattacharya, Managing Director of TCG Lifesciences commented: “We are indeed excited about this program which involves a challenging new target that could potentially address the vast incidence of nosocomial infections which plague healthcare facilities all over the world. Debiopharm’s developmental expertise combined with our medicinal chemistry capabilities and efficient discovery operations provide an attractive opportunity for accelerated discovery of novel drug candidates for clinical development.”

Antibiotic resistance and nosocomial infection
The CDC estimates that, each year, nearly 2 million people in the United States acquire an infection while in a hospital, resulting in 90,000 deaths.

More than 70 percent of the bacteria that cause these infections are resistant to at least one of the antibiotics commonly used to treat them.

In a report, the European CDC states that at least 25,000 patients in the EU die each year from infections due to bacteria that are resistant to a number of marketed drugs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Shasun Pharmaceuticals and Debiopharm Enter Into Licensing Agreement
Agreement for the manufacturing and commercialization of Huperzine-A.
Wednesday, April 10, 2013
Debiopharm and Ascepion Announce an Exclusive License Agreement
Agreement for the development and commercialization of the dual-targeting kinase Inhibitor, ASP-08126 (Debio 1144), for the treatment of oncology diseases.
Tuesday, June 19, 2012
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932
Company expects to initiate a combination Phase I/II study in NSCLC patients in the second quarter of 2012.
Tuesday, February 21, 2012
Debiopharm and Aurigene Sign Agreement for the Development and Commercialization of Debio 1142
The Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours.
Wednesday, April 27, 2011
Debiopharm Group™ Starts Phase I Clinical Trial with Debio 0932
A targeted small molecule inhibitor of heat shock protein 90 for cancer treatment.
Wednesday, April 28, 2010
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl® to Further Help Prostate Cancer Patients
Debiopharm Group announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl® (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Thursday, September 25, 2008
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!